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Abstract 
The objective of the study was to find a computational procedure to normalize solubility data determined at 
various temperatures (e.g., 10 – 50 
o
C) to values at a “reference” temperature (e.g., 25 °C). A simple procedure 
was devised to predict enthalpies of solution, ΔHsol, from which the temperature dependence of intrinsic 
(uncharged form) solubility, log S0, could be calculated. As dependent variables, values of ΔHsol at 25 °C were 
subjected to multiple linear regression (MLR) analysis, using melting points (mp) and Abraham solvation 
descriptors. Also, the enthalpy data were subjected to random forest regression (RFR) and recursive partition 
tree (RPT) analyses. A total of 626 molecules were examined, drawing on 2040 published solubility values 
measured at various temperatures, along with 77 direct calorimetric measurements. The three different 
prediction methods (RFR, RPT, MLR) all indicated that the estimated standard deviations in the enthalpy data 
are 11-15 kJ mol
-1
, which is concordant with the 10 kJ mol
-1
 propagation error estimated from solubility 
measurements (assuming 0.05 log S errors), and consistent with the 7 kJ mol
-1
 average reproducibility in 
enthalpy values from interlaboratory replicates. According to the MLR model, higher values of mp, H-bond 
acidity, polarizability/dipolarity, and dispersion forces relate to more positive (endothermic) enthalpy values. 
However, molecules that are large and have high H-bond basicity are likely to possess negative (exothermic) 
enthalpies of solution. With log S0 values normalized to 25 
o
C, it was shown that the interlaboratory average 
standard deviations in solubility measurement are reduced to 0.06 - 0.17 log unit, with higher errors for the 
least-soluble druglike molecules. Such improvements in data mining are expected to contribute to more reliable 
in silico prediction models of solubility for use in drug discovery.    
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Introduction 
This study concerns with the prediction of the temperature dependence of intrinsic solubility (S0) of 
molecules [1,2]. A recent survey of 4557 equilibrium solubility measurements (“4557” set) of druglike (mostly 
ionizable) molecules in aqueous media suggested a two-step procedure to reduce the interlaboratory variance 
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in solubility data mining [3]. First, data from ionizable molecules can be adjusted for pH effects by calculating 
the intrinsic solubility, S0, based on the ionization constant, pKa, and the reported water solubility, Sw. Second, 
data can be normalized for temperature effects, by transforming solubility measurements performed at 
various temperatures (e.g., 10 - 50 °C) to those at a benchmark value of 25 °C. With these two steps, it was 
thought to be possible to reduce the often cited interlaboratory reproducibility of 0.5 - 0.7 log unit (or even 
higher) [4-7] down to near 0.15 [3]. Such improvements in data mining are expected to yield more reliable 
in silico prediction models of solubility for use in drug discovery.  
 However, the procedure of “normalizing” temperature effects was not articulated [3]. Qualitatively, it is 
generally expected that equilibrium solubility of most druglike molecules increases with increasing 
temperature (with exceptions). As far as we know, there has not been a report of a quantitative procedure 
where the temperature dependence of solubility is predicted from the two-dimensional (2D) structure of 
molecules.  
Reported aqueous solubility values are mainly clustered around room and physiological temperatures: 
23 ± 3 (78 %) and 37 ± 5 oC (22 %), respectively [3]. For mostly simple molecules, there are some secondary 
compilations of temperature dependent solubility (e.g., Handbook of Aqueous Solubility Data by Yalkowsky 
et al. [8]). However, for druglike molecules, large published databases of temperature-dependent solubility are 
scarce. Although our focus is to improve data mining quality of solubility measurements, knowledge of the 
temperature dependence of solubility has a number of other practical applications.  
Being able to estimate the solubility temperature dependence could allow for improved planning in early 
formulation studies. For example, Ismailos et al. [9] described the unusual solubility behavior of low-soluble 
cyclosporin A in aqueous media, where the enthalpy of solution, ΔHsol, was determined to be about -53 kJ mol
-1, 
indicating an exothermic process: as temperature is raised, the solubility decreases. In contrast, most drug 
molecules are characterized by endothermic ΔHsol, with typical values ranging from +20 to +50 kJ mol
-1, often 
with uncertainty of nearly 10 kJ mol-1. The oral dosage form of cyclosporin A consisted of making a dilution 
with milk immediately before oral administration. However, the observed bioavailability was incomplete and 
erratic. To increase absorption, it was suggested [9] that a refrigerated sample of milk might be used, to keep 
more of the drug in solution (~90 μg mL-1 at 4 °C), compared to the amount dissolved in a room-temperature 
mixture (~20 μg mL-1 at 25 °C). 
In the present study we have devised a simple procedure (similar to that used to predict the temperature 
dependence of pKa values [10]) to predict the temperature dependence of log S0 from the van’t Hoff 
relationship. As dependent variables, enthalpies of solution at 25 °C, ΔHsol, were subjected to multiple linear 
regression (MLR) analysis, using melting point (mp) and the Abraham [11,12] six (“5+1”: five traditional + 
product of H-bond acidity and basicity) solvation descriptors. Also, the data were analyzed by the random 
forest regression (RFR) and recursive partition tree (RPT) methods. A total of 626 molecules were examined, 
drawing on 2040 published solubility values measured at various temperatures.  
Theory 
The integration of the van’t Hoff differential equation over a small temperature range, between T1 and T2, 
assuming the change in standard enthalpy of solution, ΔHsol
0 (kJ mol-1), to be approximately independent of 
temperature, produces:  
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Equation (1) allows one to convert log S determined at T1 in a narrow temperature range (e.g., ≈ 25-37 °C: T1 ≈ 
298.15 to 310.15 K) to a value at a reference temperature (e.g., 25 °C: T2 = 298.15 K), provided the standard 
enthalpy of solution at 25 °C, ΔHsol
0, is known.  
The enthalpy value can be determined calorimetrically or from the temperature dependence of log S. That 
is, if one plots log S vs. 1/T for a series of measurements at different T, the slope of the plotted curve 
evaluated at 25 °C is equal to -ΔHsol
0
/(2.303 R). Often such plots show some curvature, since ΔHsol
0
 is slightly 
temperature dependent, but as a first approximation one may assume linearity if the temperature interval is 
small (e.g. ≈ 25-37 °C). 
Enthalpy values determined by the slope method are subject to high uncertainty, depending on the 
precision of the solubility measurements and the temperature spanned. As an example, assume two solubility 
measurements were performed at 25 and 37 °C, and that the reproducibility in each solubility measurement is 
0.05 log unit. On rearranging Equation (1) and casting it in the propagation-of-error form (SD = standard 
deviation), 
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One of the objectives of this study is to transform intrinsic solubility, log S0
T, measured at T, to log S0
ref, the 










Tref 15.29811752.0loglog 000  (3) 
For example, if ΔHsol
0
 = +30 kJ/mol, T = 310.15 K (37 °C), and the reference temperature is selected as 25 °C, 
then log S0
ref = log S0
310.15 – 0.203. That is, the molecule is 1.6 times less soluble at 25 °C, compared to that at 
37 °C. 
 Thermodynamic standard state definition traditionally is based on concentrations being extrapolated to 
zero (unit activity) value. However, most of the measured solubility values used in Equation (1) was 
determined in saturated water solutions, with many molecules undergoing some degree of ionization. It is 
assumed that by working with intrinsic solubility values (referring to solubility of molecules in the uncharged 
form), some of the consequences of non-unit activity considerations in the definition of the standard state 
ΔHsol
0 may be mitigated, especially for sparingly soluble molecules. To highlight that intrinsic solubility is not 
determined at the standard (zero-concentration, unit activity) state, ΔHsol (without the superscript) will be 
associated with solubility measurement in saturated solutions. 
Methods 
A total of 626 enthalpies of solution were gathered, either directly from calorimetric data (12 %) or 
indirectly from temperature-dependent solubility data (88 %).  
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Van’t Hoff Analysis of Temperature-Dependent Solubility Data 
When available, the enthalpies of solution were taken directly from primary publications. Otherwise, the 
temperature-dependent intrinsic solubility values for each molecule were fitted in this study to the linear 
equation: 
log S0 = a + b/T                    (4) 
The value of ΔHsol was set equal the slope, b, multiplied by -2.303 R (cf., Equation 1). The solubility values in 
the units of the source publications (molality or molarity) were used in Equation (4). (Mole fraction units were 
converted to molality prior to fitting.) 
Calorimetric Data Sources 
Calorimetrically measured enthalpies of solution are considered to be more accurate than those derived 
from solubility as a function of temperature. A search located 77 molecules with reported calorimetric 
enthalpies of solution, all from primary literature. Table A1 in the Appendix indicates which enthalpies were 
the calorimetrically determined. 
Solubility Data Sources 
Yalkowsky et al. [8] Handbook of Aqueous Solubility Data is a reliable and convenient secondary source of 
temperature-dependent Sw values of relatively simple molecules. The data were measured by the saturation 
shake-flask method [3], and are expected to have good precision. A search led to 653 suitable Sw values for 195 
molecules, with 2-6 solubility-temperature points per molecule, in the interval 20 ± 5 to 41 ± 7 °C. The 
handbook values mainly ranged from about -0.1 to -3.5 log molarity units (mean -1.8).  
An additional 1387 measurements as a function of temperature were gathered from primary publications 
for 354 molecules, with measurements based on the shake-flask (traditional and various miniaturized variants) 
and two potentiometric (DTT and CheqSol) methods, as described elsewhere [3]. This set included more 
druglike molecules than that from the handbook, and ranged in log S0 from +2.7 to -8.4 (mean -3.0). Table A1 
indicates which enthalpies were calculated from solubility data.  
Conversion of Water Solubility (Sw) to Intrinsic Solubility (S0)  
The pDISOL-X program (www.in-adme.com/pdisol_x.html, in-ADME Research) was used to convert 
nominally unbuffered water solubility (Sw) values with unspecified pH to intrinsic values (S0) and to calculate 
the saturation pH (pHsat), as described by Völgyi et al. [13] and others [14-16]. Since no instances of ambient 
CO2 concentration were reported in solubility measurement studies, for practically-insoluble bases with pKa > 8 
(e.g., terfenadine, clofazimine), [CO2] = 10 μM was assumed in the calculation of S0. Sparingly-soluble acids 
were less affected by ambient levels of CO2. Also, in the calculations, it was necessary to assume that the 
Henderson-Hasselbalch relationship was valid [3], except when multiple-pH buffer SpH values (log S vs. pH) data 
were available to derive the corresponding S0 values.  
Data Types and Exclusions 
It was suspected that enthalpy of solution might depend on the acid-base properties of the molecule, as 
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was found in the study of the temperature dependence of pKa values [10]. The enthalpy of solution might be 
influenced by differences between the solvation effects in the proton releasing and gaining processes, or by 
the electron density of the different functional groups. Consequently, the selected compounds were assigned 
indicator indices: IA, IB, IAB, and IN, with a unit value indicating that a molecule is an acid, base, ampholyte, or 
neutral, respectively, and zero otherwise.  
Given the multitude of methods and conditions used to measure solubility [3], from which most of the 
enthalpy of solution values were derived here, and, as mentioned above, such enthalpy values are expected to 
be sensitive to errors in the log S vs. 1/T data, intralaboratory enthalpy variances are expected to be smaller 
than interlaboratory variances. About 6 % of the log S measurements were done at two temperatures, each 
result reported from a different laboratory (“n=2, different labs” set), potentially representing the least-
reliable slope-calculated enthalpy values. By contrast, in 73 % of the studies, all of the temperature-dependent 
log S measurements for a given molecule come from the same laboratory (e.g., the curated “653-set” from the 
Yalkowsky et al. handbook [8]). The latter “one source” temperature-solubility data are expected to lead to the 
most-reliable calculated enthalpy values.  
For each molecule, the log S values were separated into two groups: those determined at t < 30 °C (“room 
temperature set”, RT) and those at t ≥ 30 °C (“physiological temperature set”, PT). For each grouping, the 
standard deviation (SDRT, SDPT) values were calculated for each molecule based on replicate measurements. 
The average of all SD values was 0.18 log unit for the dataset. A given molecule with SD greatly exceeding the 
average value would be excluded from the training and test sets. 
Since we are only using 2D molecular descriptors, different solvates of a given compound were lumped 
together with nonsolvates for the compound (when this information was available).  
 Of the 626 enthalpies of solution located/calculated, some values were suspected to be unreliable. We 
applied three filters to systematically exclude those points from training and test sets from the start, but their 
predicted ΔHsol values were calculated nevertheless (Table A1).  
 Three systematic exclusion criteria were: 
 The “n=2, different labs” data were excluded from model training and testing.  
 If for a given molecule, SDRT or SDPT > 0.3, the data were excluded from the model training and testing. 
 Solubility-derived enthalpies were excluded if slope-calculated values of ΔHsol < -80 or > +80 kJ mol
-1, 
based on the observation that in the best-quality (calorimetric) data, enthalpy data ranged from -37 to 
+50 kJ/mol. We put an arbitrary cut-off of ±80 kJ mol-1 in the expectation that erratic values calculated 
from solubility-temperature data would less likely enter the training set.  
On applying the above criteria, 55 compounds were excluded. Thus 571 molecules were selected for the 
training and test sets. In the 571-set, 43 % were acids, 13 % were bases, 27 % were ampholytes, and 17 % were 
nonionizable molecules. The above ionization type distribution is not ideally suggestive of druglike molecules, 
which include more bases than acids. For the 77 calorimetrically measured ΔHsol, the average value is 
+13 kJ mol-1, with values ranging from -37 to +50 kJ mol-1. By comparison, the log S vs. T derived ΔHsol have the 
average value +21 kJ/mol, and the much wider range from -97 to +120 kJ/mol (before exclusions). 
Variances of Replicate ΔHsol 
 In the 626 enthalpy set, there were 99 instances of replicate ΔHsol values, measured in different 
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laboratories. The average standard deviation in the replicates was 7 kJ mol
-1
, in line with expectations that the 
quality of the data were limited by the expected uncertainties in log S measurement (error ≥ 0.05 log unit), as 
considered in the Theory section.  
Prediction of Enthalpy of Solution 
The random forest regression (RFR) method is a powerful and easy-to-use new statistical (albeit somewhat 
of a “black box”) tool which can cope with very large numbers of correlated descriptors, something that is not 
possible with traditional multiple linear regression (MLR) methods. It was thus a good starting point for our 
enthalpy data analysis. Using RFR could reveal sensitive descriptors that might not have been otherwise 
obvious. The recursive partition tree analysis provides a simple alternative view of the characteristics of the 
data in relation to the descriptors. However, the important advantage of the MLR analysis is that the results 
are thought to be easier to understand, in terms of the role of specific descriptors in the prediction of 
physicochemical properties, such as the temperature dependence of solubility.  
The RFR modeling (Walters [17] – very useful tutorial) was first explored, starting with the 193 descriptors 
(“RDK” set, including lipophilicity as indicated by log P and log D, connectivity and molecular shape indices, 
topological and electrotopological state indices, surface area contributions, partial atomic charges, H-bond 
donor/acceptor counts, molecular refractivity, and other more specialized descriptors) calculated by the open-
source chemoinformatics and machine-learning RDKit library of programs (Landrum et al. [18]; 
http://rdkit.readthedocs.org/en/latest/), combined with the six Abraham solvation descriptors [11,12], along 
with the acid-base indicators (IA, IB, IAB, and IN), and the published melting points (mp). Where the latter values 
were not found, the Lang and Bradley [19] predicted melting points in the QsarDB open repository of data and 
prediction tools (http://qsardb.org/repository/handle/10967/104) [20] were used. Table A1 indicates which 
mp was calculated and which was experimental.  








: H-bond acidity and basicity, and the 
product of the two; π2: dipolarity/polarizability; R2: dispersion force; and Vx: molar volume – see Glossary of 
Terms for further elaboration) were estimated from the 2D structure of molecules using ADME Boxes v4.9 
program from ACD/Labs (Advance Chemistry Development, Inc., www.ACDLabs.com). Perhaps better fits 
might be expected from descriptors derived directly from measurements rather than from in silico predictions. 
However, experimentally-based ABSOLV values may not be available for all the compounds considered here. 
After the RFR modeling, recursive partition tree analysis and multiple linear regression (MLR) calculations 
were explored, using the Algorithm Builder v.1.8 program from ACD/Labs. 
SMILES representations of the 2D structures of molecules were available at the Royal Society of Chemistry 
ChemSpider website: http://www.chemspider.com/. ACD/ChemSketch from ACD/Labs was used to construct 
“SDF/mol” format 2D representations of the molecules.  
Model Validations 
The RFR method randomly selected 30% of the data to be test sets. The RTP method was not validated with 
a test set, since it was used in a qualitative way. In the MLR method, the “leave-many-out” (LMO) cross-
validation procedure (20 % of the measurements randomly excluded in 100 different repeated combinations), 
where a cross-validated q2 was used to assess model predictivity.  
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Results and Discussion 
Random Forest Regression (RFR) Analysis 
As summarized in Table 1, four different combinations were tried using random forest regression analysis: 
(I) calorimetric data only - mp, RDK, ABSOLV descriptors; (II) calorimetric + solubility-derived data - mp, RDK, 
ABSOLV descriptors; (III) like Case II, but without ABSOLV descriptors; and (IV) like Case II, but excluding RDK 
descriptors.   
The small calorimetric set (Case I) was best predicted. The root-mean-square (RMS) error was 11.7 kJ mol-1; 
61 % of the variances were predicted. The 10-most sensitive descriptors are shown in Table 1 for this case. At 
the top of the list is mp. Four of the six ABSOLV descriptors were among those in the top list.  
The combined calorimetric + solubility-derived set (II) included all the “571-set” data and the full set of 
descriptors. The RMS error was slightly higher at 13.9 kJ mol-1; 35 % of the variances were predicted, which 
suggests that the solubility-based data dragged down the overall precision of the combined data set. The mp 
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descriptor was in the second position from the top, but there were no ABSOLV descriptors showing up in the 
top-10 list. The most sensitive RDK descriptors included fractions of sp
3
 carbon, molecular refractivity – surface 
area [22], log P – surface area [22], various Hall-Kier electrotopological, connectivity and molecular shape 
indices, and log P [23]. 
Cases III and IV excluded either RDK or ABSOL descriptors. The statistics were similar to those of the full-
complement of descriptors (II), with RMS errors rising slightly to 14.4 and 15.1 kJ mol
-1
 for the RDK (III) and the 
ABSOLV (IV) cases, respectively, and with accounted variances decreasing slightly. In Case IV (ABSOLV), the 
order of sensitivities comprised: mp > Vx > Σβ2




Recursive Partition Tree (RPT) Analysis 
 The “571-set” exclusion-filtered data (calorimetry + solubility-derived), with mp + ABSOLV + acid-base 
indicator indices (IA, IB, IAB, IN) as descriptors, was next subjected to recursive partition tree analysis (Algorithm 
Builder v.1.8). Figure 1 shows the decision tree. 
The first node automatically separated the acids from the non-acids. Within the acid set, mp ≥ 303 °C 
further split the group into two. There are 9 molecules in the higher mp set, with average ΔHsol = 47 ± 13 
kJ mol-1. The compounds with the lower mp included 235 molecules, with average ΔHsol = 27 ± 12 kJ mol
-1.  
For the non-acids, Σβ2
H
 ≥ 3.8 split the set into two groups. The group with strong H-bond acceptors included 
8 molecules, with average ΔHsol = -24 ± 11 kJ mol
-1
, associated with an exothermic process. The 319 molecules 
in the weaker H-bond basicity group were split into two subsets according to molar refractivity, R2 ≥ 0.47. The 
279 molecules with stronger dispersion force interaction (arising from pi- and n-electrons of the solute) had 
the average ΔHsol = 19 ± 17 kJ mol
-1
, whereas the 40 “hard” molecules had the lower average 2 ± 15 kJ mol
-1
. 
Multiple Linear Regression (MLR) Analysis 
 Table 2 summarizes the multiple linear regression analysis of the enthalpy data, using the mp + ABSOLV + 
acid-base indicator indices (IA, IB, IAB, IN) descriptors.  
The calorimetric case (A) again was best-fit, with r2 = 0.67 and s = 10.8 kJ mol-1. The statistics were 
comparable to those found in the RFR analysis for the same set. Unlike the RFR method, it may be easier to 
interpret the contributions of each of the ABSOLV descriptors. The four acid-base indicator indices in effect 
acted as four different intercepts: acids and ampholytes had positive additive contributions, whereas bases 
and neutrals had negative contributions, in addition to those trends predicted by the mp + ABSOLV 
descriptors. The H-bond basicity (Σβ2
H) led to negative (exothermic) enthalpy contributions, whereas π2 (solute 
polarity/polarizability due to solute-solvent interactions between bond dipoles and induced dipoles) 
contributed to positive (endothermic) enthalpy values. The other ABSOLV descriptors made smaller 
contributions in the Case A model. Enthalpy of solution was predicted to increase with increasing melting 
points. Figure 2a shows the correlation plot for the calorimetric set. As can be seen, acids tend to have higher 
positive enthalpies compared to the other molecules. 
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Figure 1. Recursive partition tree analysis (Algorithm Builder, v.1.8), separating acids from non-acids. For acids, 
mp is a key discriminator. For non-acids, H-bond basicity and molar refractivity are key discriminators. 
 
 
The non-calorimetric case (B) was predicted less well, compared to the above calorimetric case, just as in 
the case in RFR analysis. There was less acid-base differentiation, as indicated by the similarity of four I-indices. 
The other main difference between Cases A and B is that the dispersion-force R2 played a more prominent role 
in Case B than the dipolarity/polarizability π2, with high values predicting more positive (endothermic) 
enthalpies. Also, compounds with larger McGowan molar volumes (Vx) were associated with more negative 
(exothermic) enthalpies.  
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The recursive partitioning tree analysis 
suggested that acids could be grouped 
separately from the non-acids. Cases C 
and D tested that idea. The acids had a 
muted contribution from ABSOLV 
descriptors (except for the H-bond 
acidity), compared to the non-acids, as is 
indicated in Table 2. For example, a 







 descriptors yielded r
2
 = 0.04, s = 
12.1, and F = 321; a model using just IA 
and mp yielded r
2
 = 0.03, s = 12.1, and F = 
641. Figure 2(b) shows the correlation 
plot, combining the Case C and D sets. 
The acids are on the high positive 
enthalpy side of the plot. Most of the 
molecules that have very negative 
enthalpy values are large complex species 
(e.g., cyclosporine A, clarithromycin, 
erythromycin, ivermectin, digoxin, and 
digitoxin). 
The calculated enthalpy of solution 
values in Table A1 are based on Case D 
applied to acids and Case C applied to 
non-acids. Very similar results were 
obtained from the application of 
combined Case E model (not shown). This 
Cases C+D method of calculation has 
been incorporated into the current 
release of pDISOL-X, where intrinsic 
solubility, log S0, are now predicted both 
at 25 and 37 °C. 
 
Interlaboratory Errors Temperature Effect 
Figure 3 displays the ratios of standard deviations (SD) calculated from replicates from temperature 
uncompensated log S0 values, SD(T), to those calculated from temperature normalized data, SD(25 °C), plotted 
against the normalized SD. If the interlaboratory errors in log S0 measurement were attributable entirely to 
temperature effects, then the SD(T)/SD(25 °C) ratio would greatly exceed unity. On the other hand, if there 
were large systematic errors in log S0 measurements not related to temperature, then the ratio would be near 
one.  
When the Case C and D models were applied to the “4557-set” data [3], 94 % of the calculated 
 
 
Figure 2. (a) The correlation plot for the calorimetric set (Case 
A in Table 2), where acids (unfilled circles) tend to have 
higher positive enthalpies compared to the other molecules. 
(b) The correlation plot for both calorimetric and solubility-
based data (Case C+D in Table 2). The statistics were 
calculated the SigmaPlot plotting program. The acids (unfilled 
circles) dominate the high positive enthalpy side of the plot. 
Molecules with very negative enthalpy values are large 
complex species with many H-bond acceptor groups (e.g., 
cyclosporine A, clarithromycin, erythromycin and ivermectin. 
 




 - log S0
T
 differences were between +0.2 and -0.2. If the non-temperature related errors are 
substantially greater than 0.2, then temperature normalization barely lowers interlaboratory errors. Figure 3 
illustrates the impact of normalizing intrinsic solubility data to the 25 °C benchmark temperature. 
Figure 3a represents high-quality solubility measurements from the Yalkowsky et al. [8] handbook, albeit of 
relatively simple molecules. The interlaboratory errors are reduced 7.8-fold on the average, to an average 
value SD(25 °C) = 0.06 log unit.  
 Figure 3b depicts a larger set of molecules, with a higher proportion of druglike molecules, which are less 
soluble than those in the case of Figure 3a. The interlaboratory errors are reduced 2.2-fold on the average, to 
an average value of SD(25 °C) = 0.17 log unit. It is evident that interlaboratory errors not related to ionization 
and temperature effects are higher in the druglike set of molecules. 
Remaining Challenges in the Prediction of Enthalpy of Solution 
Table A1 also lists the calculated enthalpy values for the 55 molecules excluded from direct model 
construction. It is not a “validation” set, since many of the measurements were suspect, following the 
exclusion criteria. As it turns out, the calculated enthalpies of many of the excluded molecules are at 
comparable levels of agreement to the experimental enthalpy values. However, some compounds did show 
high variance. Mostly, these had reported negative enthalpies of solution, but the model calculated positive 
values (e.g., celecoxib, clotrimazole, droperidol, indinavir, ezetimibe, famotidine, fenofibrate, glibenclamide, 
loratidine, meloxicam, quetiapine, and saquinavir). Some excluded molecules had very high positive reported 
enthalpies, which the model only partly matched (triflupromazine, chlorpromazine, triflupromazine, etoxadrol, 
and rosiglitazone). It is suspected that data precision may be an underlying cause of the poor predictions. It is 
possible that some molecules may have been measured over a temperature range encompassing the Krafft or 
clouding points, which would have contributed to a highly nonlinear van’t Hoff plot. Complications in solution 
chemistry, such as the formation of low-order aggregates, micelles, and complexes (with solution constituents) 
may contribute to increased errors [13-16]. For example, Pobudkowska et al. [25] found that aggregate-
forming chlorpromazine, triflupromazine, and trifluoperazine (S0 0.5, 1.1, and 2.7 μg mL
-1, resp.) showed 
exceptionally high solubility temperature dependence, compared to more soluble (> 10 μg mL-1) phenothiazine 
derivatives. It would be helpful to measure the enthalpies of such molecules by direct calorimetry, to better 
understand the nature of the interlaboratory errors. 
Calculated Negative Enthalpies of Solution 
As listed in Table A1, there were 11 calculated negative values based on the Case C+D models, compared to 
51 (non-excluded) negative measured values, with about half of these being about a standard deviation from 
zero. The average Abraham descriptors for the calculated negative enthalpy set were 0.9 (Σα2
H), 3.8 (Σβ2
H), 3.6 
(π2), 2.5 (R2), and 5.3 (Vx). Given the MLR coefficients, the negative contributions were equally from H-bond 
basicity and the McGowan volume (-65 kJ mol-1 contribution), but these were somewhat offset by positive 
contributions from dipolarity and molar refractivity (+40 kJ mol-1 contribution), resulting in a net negative 
calculated average enthalpy (-17 kJ mol-1). The RPT decision tree indicates that eight non-acids with H-bond 
basicity exceeding 3.8 had an average enthalpy of -24 ± 11 kJ mol-1 (node N01, Figure 1). There were 40 
additional compounds with near zero enthalpy (node N000 in Figure 1). 
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Figure 3. Standard deviations in log S0 determined in replicates at multiple temperatures, SD(T), divided by those 
from log S0 transformed to the reference temperature, SD(25
o
C), as a function of SD(25 °C). (a) High-quality 
solubility measurements from the Yalkowsky et al. [8] handbook, for relatively simple molecules. (b) The SD ratios 
for the entire “4557” set containing a large number of druglike molecules. 
 MLR Model Validation  
 The developed MLR model was validated by the leave-many-out (LMO) method, using the Algorithm 
Builder V1.8 program. In the approach, 20 % of the dependent variables were randomly removed, with the 
MLR repeated 100 times, produced the q2 = 0.27, with the q2 standard deviation of 0.07. These values are only 
slightly less than the value of r2 (0.31) determined by normal MLR analysis. 
Conclusion 
The three different prediction methods tested (RFR, RPT, MLR) all indicated that the error in the enthalpy of 
solution data are 11-15 kJ mol
-1
, which is similar to estimates calculated from propagation-of-errors in 
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solubility measurements (~10 kJ mol
-1
) and with estimates based on interlaboratory replicates (~7 kJ mol
-1
). 
According to the combined MLR model (Cases C+D or E, Table 2), higher values of mp, H-bond acidity (Σα2
H
), 
polarizability/dipolarity (π2), and dispersion forces (R2) lead to more positive enthalpy values. Furthermore, big 
molecules (large Vx) that have high H-bond basicity (Σβ2
H
) are associated with more negative enthalpies of 
solution.   
The main objective of this study was to demonstrate that the interlaboratory errors in solubility data 
mining can be lowered if solubility data are normalized for temperature effects. Before adjusting for ionization 
and temperature effects, the expected errors are commonly thought to be 0.5 – 0.7 (or greater) log unit [4-7]. 
After transforming Sw to S0 values (adjusting for ionization), it was estimated that temperature normalizations 
could lower the interlaboratory errors to near 0.15 log unit [3]. In the current study, we have shown this to be 
the case. Thus, for simple and moderately soluble molecules, the average interlaboratory errors are estimated 
to be about 0.06 log unit, lower than the 0.17 value estimated for sparingly-soluble druglike molecules. 
Consequently, the commonly cited interlaboratory solubility error of 0.5 – 0.7 log unit in data mining warrants 
revision. It is thus expected that improved data quality will spur improved in silico prediction of solubility of 
druglike molecules. 
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Glossary of Terms 
MLR multiple linear regression 
RDK RDKit generated descriptors 
RFR random forest regression method  
RPT recursive partition tree analysis 
IA, IB, IAB, IN  acid-base indicator indices: unit value, indicating that a molecule is an acid, base, ampholyte, or 
neutral, respectively, and zero otherwise 
Σα2
H Abraham descriptor – solute H-bond total acidity (also called A)  
Σβ2
H Abraham descriptor – solute H-bond total basicity (also called B)  
π2 Abraham descriptor – solute polarity/polarizability due to solute-solvent interactions between bond 
dipoles and induced dipoles (also called S)  
R2 Abraham descriptor – excess molar refraction (dm
3 mol-1 / 10); which models dispersion force 
interaction arising from pi- and n-electrons of the solute (also called E)  
Vx Abraham descriptor – McGowan molar volume (dm
3 mol-1 / 100) of the solute  
Σα2
H·Σβ2
H Abraham acid-base H-bonding product descriptor [12] 
S solubility, ideally expressed in units of mol/L (M), μg/mL, or mg/mL  
S0 “intrinsic” solubility (i.e., the solubility of the uncharged form of the compound) 
Sw “water” solubility, defined by dissolving enough pure free acid/base (not drug salt) in distilled water 
(or water containing an inert salt - as ionic strength adjustor) to form a saturated solution. The final pH 
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of the suspension, pHsat, and S0 can be calculated by the Henderson-Hasselbalch equation (when valid), 
provided the true pKa is known.  
SpH  “pH buffer” solubility (i.e., the total solubility of the compound at a well-defined measured pH) 
ΔHsol
0
 change in enthalpy of solution at 25 °C for uncharged molecules (ΔHsol implies the saturated-solution 
reference state, rather than the one based on unit activity)  
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Appendix 
 Table A1 lists the molecules studied, along with the mp and ABSOLV descriptors. 
 
Table A1. Enthalpy of Solution, Melting Points, and Abraham Solvation Descriptors 


























(B) π  (S) R2 (E) 
Mc 
Gowan 
Vol. (Vx) References 
d
 
(2-naphthoxy)acetic acid A 56 29 156 0.57 0.72 1.56 1.51 1.50 [26] 
[4-(benzyloxy)phenyl]acetic acid A 46 28 123 0.57 0.75 1.64 1.38 1.88 [27] 
1,1-bis(acetyloxy)propyl acetate N -4 -5 31 0.00 1.07 1.32 0.17 1.60 [28] 
1,1-bis(butanoyloxy)propyl_butanoate N -6 -12 27 0.00 1.09 1.35 0.16 2.45 [28] 
1,1-bis(propanoyloxy)propyl propanoate N -7 -9 30 0.00 1.08 1.34 0.17 2.02 [28] 
1,4-butanediol  N -11 6 20 0.63 0.59 0.73 0.41 0.79 [29] 
1,4-diaminobutane B -37 4 27 0.42 1.12 0.82 0.40 0.87 [29] 
17α-methyltestosterone N -13 13 164 0.31 1.02 2.22 1.53 2.52 [30-32] 
1-butyltheobromine (excluded**) N 0 12 108 0.00 1.28 1.92 1.47 1.79 [32,33] 
1-naphthylamine (excluded**) B 2 24 49 0.23 0.49 1.40 1.58 1.19 [34,35] 
2-benzoyloxy ethanol (excluded**) N 7 9 78 0.23 0.82 1.25 0.88 1.27 [31,36] 
2,3-dichloro-L-tyrosine AB 22 17 175 1.30 1.13 1.60 1.35 1.62 [37] 
2,3-quinolino-phthalide (Form I) AB 49 27 208 0.13 1.15 2.12 2.48 2.10 [38] 
2,3-quinolino-phthalide (Form II) AB 11 29 215 0.13 1.15 2.17 2.45 1.96 [38] 
2,3-quinolino-phthalide (Form III) AB 13 23 203 0.13 1.07 1.65 1.90 1.63 [38] 
2,3-quinolino-phthalide (Form IV) AB 16 24 206 0.13 1.07 1.71 1.88 1.49 [38] 
2,3-quinolino-phthalide (Form V) AB 25 23 200 0.13 1.07 1.65 1.90 1.63 [38] 
2,4,6-trichlorophenol (excluded) A -28 26 67 0.42 0.15 0.94 1.07 1.14 [39,40] 
2-acetamido-N-methylacetamide N 2 11 117 0.51 1.15 1.92 0.62 1.04 [41] 
2-aminopyridine B 4 18 58 0.23 0.62 1.14 0.92 0.78 [42] 
2-aminopyrimidine B 4 21 126 0.23 0.70 1.18 0.96 0.73 [42] 
2-furoic acid A 39 26 134 0.57 0.48 0.95 0.53 0.75 [43] 
2-furoic acid A 40 26 134 0.57 0.48 0.95 0.53 0.75 [44] 
2-methoxybenzoic acid A 29 25 99 0.57 0.66 1.17 0.81 1.13 [45] 
2-methylanthracene N 46 28 206 0.00 0.23 1.28 2.02 1.60 [46-48] 
2-methylanthracene N 47 28 206 0.00 0.23 1.28 2.02 1.60 [49] 
2-nitroaniline (excluded**) N -5 18 72 0.18 0.48 1.44 1.16 0.99 [34,50] 
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3,5-dibromo-L-tyrosine (anhyd.) AB 17 20 175 1.03 1.10 1.69 1.69 1.72 [37] 
3,5-dibromo-L-tyrosine (hydrated) AB 28 20 175 1.03 1.10 1.69 1.69 1.72 [37] 
3,5-diiodo-DL-tyrosine AB 24 26 213 1.03 1.14 1.82 2.31 1.89 [37] 
3,5-diiodo-L-tyrosine AB 33 26 200 1.03 1.14 1.82 2.31 1.89 [37] 
3,5-diodo-L-tyrosine AB 33 26 200 1.03 1.14 1.82 2.31 1.89 [51] 
3-aminopyridine B 3 18 61 0.23 0.71 1.21 0.90 0.78 [42] 
3-hydroxybenzoic acid A 32 30 203 1.06 0.72 1.29 0.98 0.99 [43] 
3-hydroxybenzoic acid A 33 30 203 1.06 0.72 1.29 0.98 0.99 [52] 
3-nitrobenzoic acid A 26 29 142 0.64 0.54 1.65 1.02 1.11 [32,34,53,54] 
3-nitrobenzoic acid A 28 29 142 0.64 0.54 1.65 1.02 1.11 [43] 
4-(dimethylamino)benzoic acid, methyl ester B 27 23 372 0.00 0.79 1.26 0.88 1.45 [55] 
4-aminobenzoic acid, Methyl ester B 28 18 112 0.23 0.76 1.42 0.95 1.17 [56] 
4-aminomethylbenzoate (excluded**) B 27 18 112 0.23 0.76 1.42 0.95 1.17 [31,57] 
4-aminopyridine B 4 21 159 0.23 0.71 1.21 0.90 0.78 [42] 
4-dimethylaminopyridine B 3 15 112 0.00 0.74 1.04 0.84 1.06 [42] 
4-ethyl-5-isonicotinoyl-1,3-dihydro-2H-
imidazol-2-one 
AB 16 22 189 0.36 1.48 2.27 1.57 1.60 [58] 
4-hydroxybenzoic acid A 42 30 215 1.00 0.72 1.29 0.98 0.99 [43,45] 
4-hydroxyphenylacetic acid A 40 28 150 1.07 0.72 1.29 0.98 1.13 [43] 
4-methoxybenzoic acid A 28 27 184 0.57 0.66 1.17 0.81 1.13 [45] 
4-methylaniline B 1 17 44 0.23 0.43 1.02 0.88 0.96 [32,34] 
4-methylbenzoic acid A 24 28 180 0.57 0.44 1.02 0.77 1.07 [43] 
4-methylphenol A 3 24 34 0.50 0.39 0.85 0.81 0.92 [59] 
4-nitroaniline (excluded**) B 32 26 147 0.28 0.53 1.65 1.13 0.99 [34,50] 
8-hydroxyquinoline AB -4 20 76 0.07 0.73 1.36 1.55 1.10 [32,60,61] 
9,10-dimethylanthracene N 48 26 182 0.00 0.23 1.22 2.04 1.74 [49] 
9-methylanthracene N 42 23 75 0.00 0.23 1.28 2.02 1.60 [49] 
Acetamide N 10 18 81 0.49 0.57 1.09 0.42 0.51 [62] 
Acetamide N 6 13 222 0.49 0.57 1.09 0.42 0.51 [63] 
Acetaminophen A 20 29 170 0.91 0.93 1.66 1.12 1.17 [64] 
Acetaminophen A 23 29 170 0.91 0.93 1.66 1.12 1.17 [65] 
Acetaminophen A 23 29 170 0.91 0.93 1.66 1.12 1.17 [66] 
Acetaminophen A 29 29 170 0.91 0.93 1.66 1.12 1.17 [32,67,68,83,84] 
Acetanalide, 4-methoxy- N 26 24 400 0.41 0.87 1.55 0.96 1.31 [55] 
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Acetanilide N 18 15 114 0.41 0.67 1.42 0.89 1.11 [31,32,70] 
Acetanilide N 21 15 114 0.41 0.67 1.42 0.89 1.11 [71] 
Acetanilide, 2-NH2- B 32 22 135 0.65 0.94 1.76 1.22 1.21 [72] 
Acetazolamide A 34 31 260 0.85 1.50 2.55 1.64 1.34 [32,68,73-75] 
Acetophenone, 4-HO- A 39 27 110 0.66 0.70 1.34 1.02 1.07 [76] 
Acetyl-r-mandelic acid A 45 25 97 0.57 0.81 1.47 0.82 1.43 [77] 
Acetylsalicylic acid A 23 26 142 0.57 0.77 1.42 0.84 1.29 [43] 
Acetylsalicylic acid A 26 26 142 0.57 0.77 1.42 0.84 1.29 [68,70,78-82] 
Acetylsalicylic acid (Form_I) A 38 26 135 0.57 0.77 1.42 0.84 1.29 [85] 
Acetylsalicylic acid (Form_II) A 32 26 135 0.57 0.77 1.42 0.84 1.29 [85] 
Acetylsalicylic acid (Form_IV) A 28 26 135 0.57 0.77 1.42 0.84 1.29 [85] 
Acyclovir AB 24 19 255 0.65 2.18 1.95 2.04 1.52 [79,86-89] 
Adenine AB 24 36 363 0.60 0.98 1.79 1.74 0.92 [90] 
Adipic acid A 33 26 153 1.14 0.70 1.07 0.34 1.10 [91] 
Adipic acid A 34 26 153 1.14 0.70 1.07 0.34 1.10 [92] 
Adipic acid A 36 26 153 1.14 0.70 1.07 0.34 1.10 [43] 
Adipic acid A 38 26 153 1.14 0.70 1.07 0.34 1.10 [65] 
Adipic acid, 3-Methyl- A 56 25 101 1.14 0.73 1.06 0.34 1.24 [93] 
Ajmaline B 8 20 206 0.63 1.68 1.87 2.49 2.46 [8] 
Alanine, D- AB 8 16 291 0.78 0.93 0.92 0.38 0.71 [51] 
Alanine, DL- AB 9 14 264 0.78 0.93 0.92 0.38 0.71 [51] 
Alanine, DL- AB 8 15 245 0.78 0.93 0.92 0.38 0.71 [63] 
Alanine, DL- AB 11 9 112 0.78 0.93 0.92 0.38 0.71 [94-97] 
Alanine, L- AB 8 17 315 0.78 0.93 0.92 0.38 0.71 [98] 
Alanine, L- AB 8 16 291 0.78 0.93 0.92 0.38 0.71 [51] 
Albendazole AB 22 22 174 0.71 1.12 1.96 2.01 1.95 [99-101] 
Albuterol AB 5 4 151 1.19 1.82 1.26 1.43 1.98 [8] 
Alclofenac A 15 26 92 0.57 0.70 1.32 1.06 1.63 [102] 
Allobarbital A 26 26 171 0.52 1.32 1.47 1.22 1.57 [103] 
Allopurinol A 49 29 350 0.27 1.54 1.04 1.43 0.88 [66] 
Amifloxacin AB 22 13 198 0.71 2.34 2.58 2.18 2.37 [104] 
Aminopenicillanic acid, 6-(+)- AB 4 13 202 0.80 1.94 1.69 1.59 1.47 [105-108] 
Aminopyrine B 7 12 135 0.00 1.79 1.88 1.56 1.87 [119] 
Aminopyrine (Form A) B 12 12 135 0.00 1.79 1.88 1.56 1.87 [8,68,110] 
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Amobarbital A 27 25 157 0.57 1.50 1.54 1.16 1.80 [103] 
Amoxicilin x 3H2O AB 19 15 196 1.55 2.90 3.22 2.70 2.54 [86,105,111-113] 
Ampicillin AB 25 16 204 1.06 2.62 3.01 2.48 2.48 
[8,105,106,111, 
113,114] 
Ampicillin x 3H2O AB 7 15 198 1.06 2.62 3.01 2.48 2.48 [2,8,68,111,113] 
Andrenosterone N 25 21 220 0.00 1.31 2.99 1.77 2.36 [116] 
Androsterone N 25 14 185 0.31 0.96 2.21 1.43 2.43 [116] 
Aniline, 2-NO2- N 36 18 72 0.18 0.48 1.44 1.16 0.99 [117] 
Aniline, 3-NO2- B 35 23 72 0.30 0.53 1.65 1.13 0.99 [117] 
Aniline, 4-NO2- B 37 23 72 0.28 0.53 1.65 1.13 0.99 [117] 
Anthracene N 45 30 216 0.00 0.23 1.34 1.99 1.45 [49] 
Anthracene N 47 30 216 0.00 0.23 1.34 1.99 1.45 [46-48] 
Anthracene N 48 30 216 0.00 0.23 1.34 1.99 1.45 [118] 
Antipyrine B 20 17 114 0.00 1.28 1.75 1.42 1.49 [119] 
Antipyrine B 23 17 112 0.00 1.28 1.75 1.42 1.49 [8,31,110] 
Antipyrine, 4-NH2- B 25 15 109 0.21 1.72 1.91 1.65 1.58 [119] 
Apigenin A 29 36 348 1.30 1.20 2.25 2.36 1.85 [120] 
Aprobarbital A 21 25 141 0.52 1.29 1.40 1.11 1.61 [103] 
Arginine, D- AB 5 7 235 1.26 1.95 1.24 1.06 1.39 [51] 
Arginine, DL- AB 18 7 230 1.26 1.95 1.24 1.06 1.39 [121] 
Arginine, L- AB 19 8 244 1.26 1.95 1.24 1.06 1.39 [122] 
Ascorbic  acid A 22 25 187 1.12 1.84 1.93 1.42 1.11 [43] 
Ascorbic  acid A 23 25 187 1.12 1.84 1.93 1.42 1.11 [44] 
Asparagine, L- AB 24 17 235 1.27 1.48 1.84 0.80 0.96 [51] 
Asparagine.H2O, L- AB 34 15 235 1.58 1.77 2.07 0.89 1.13 [51] 
Aspartic acid, DL- AB 29 15 270 1.18 1.26 1.37 0.55 0.92 [51] 
Aspartic acid, DL- AB 31 15 270 1.18 1.26 1.37 0.55 0.92 [45] 
Aspartic acid, L- AB 24 14 230 1.18 1.26 1.37 0.55 0.92 [51] 
Aspartic acid, L- AB 27 14 230 1.18 1.26 1.37 0.55 0.92 [45] 
Atovaquone (excluded**) A 8 34 224 0.31 1.21 2.54 2.49 2.69 [123,124] 
Atrazine B 27 17 173 0.36 0.89 1.24 1.26 1.62 [8,70,125] 
Azelaic acid A 38 25 104 1.14 0.71 1.09 0.33 1.53 [126] 
Azelaic acid A 39 25 104 1.14 0.71 1.09 0.33 1.53 [43] 
Aztreonam AB 33 18 227 0.84 2.66 3.62 2.46 2.76 [127] 
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Barbital (Form_I) A 19 26 190 0.52 1.21 1.35 0.98 1.37 [128] 
Barbital (Form_II) A 17 26 190 0.52 1.21 1.35 0.98 1.37 [129] 
Barbital (Form_III) A 30 26 190 0.52 1.21 1.35 0.98 1.37 [128] 
Barbituric acid, 5,5-propyl-2- A 24 25 146 0.52 1.21 1.36 0.98 1.66 [130] 
Barbituric acid, 5-allyl-5-buthyl- A 13 25 145 0.52 1.27 1.42 1.10 1.75 [130] 
Barbituric acid, 5-allyl-5-phenyl- A 24 28 157 0.52 1.34 1.87 1.68 1.80 [130] 
Barbituric acid, 5-Me-5-phenyl- A 25 29 226 0.52 1.29 1.80 1.56 1.56 [130] 
Barbituric acid, i-Pr- A 24 27 215 0.52 1.23 1.38 1.02 1.23 [130] 
Benzamide N 18 19 130 0.49 0.66 1.55 1.00 0.97 [63] 
Benzenepentacarboxylic acid A 29 25 212 2.86 1.76 2.61 1.52 1.79 [131] 
Benzenesulfonamide, 2-NH2- AB 34 21 155 0.67 1.18 1.94 1.44 1.20 [132] 
Benzenesulfonamide, 3-NH2- AB 39 21 141 0.67 1.14 1.92 1.44 1.20 [132] 
Benzenesulfonamide, 4-amino-N-(2,3-
dichlorophenyl)- 
AB 14 29 194 0.66 1.05 2.63 2.21 2.05 [133] 
Benzenesulfonamide, 4-amino-N-(2,5-
dichlorophenyl)- 
AB 24 29 192 0.66 1.05 2.66 2.23 2.05 [133] 
Benzenesulfonamide, 4-amino-N-(3,4-
dichlorophenyl)- 
AB 30 30 193 0.71 1.05 2.66 2.23 2.05 [133] 
Benzenesulfonamide, 4-amino-N-(4-
chlorophenyl)- 
AB 38 28 185 0.64 1.12 2.59 2.12 1.93 [133] 
Benzenesulfonamide, N-(2,3-dichlorophenyl)- A 28 31 114 0.43 0.74 2.21 1.90 1.95 [134] 
Benzenesulfonamide, N-(2-chlorophenyl)- A 15 30 125 0.36 0.81 2.14 1.79 1.83 [134] 
Benzenesulfonamide, N-(4-chlorophenyl)- A 38 30 122 0.42 0.81 2.17 1.82 1.83 [134] 
Benzenesulfonic acid, 3-NH2- (anhyd.) AB 19 27 300 0.67 1.14 1.92 1.44 1.20 [135] 
Benzenesulfonic acid, 4-NH2- AB 21 19 122 0.54 1.19 2.20 1.17 1.16 [136] 
Benzocaine B 41 15 89 0.23 0.76 1.43 0.94 1.31 [55] 
Benzocaine B 35 16 91 0.23 0.76 1.43 0.94 1.31 [31,32,57,68,78] 
Benzoic acid A 26 26 122 0.57 0.44 1.08 0.75 0.93 [43] 
Benzoic acid A 27 26 122 0.57 0.44 1.08 0.75 0.93 [53] 
Benzoic acid A 28 26 122 0.57 0.44 1.08 0.75 0.93 [131] 
Benzoic acid A 35 26 122 0.57 0.44 1.08 0.75 0.93 
[32,53,68,137-
140] 
Benzoic acid, 2-NO2- A 25 29 146 0.57 0.54 1.65 1.02 1.11 [53] 
Benzoic acid, 3-Me-6-NO2- A 39 28 135 0.57 0.54 1.59 1.04 1.25 [141] 
Benzoic acid, 3-NO2- A 31 29 141 0.64 0.54 1.65 1.02 1.11 [53] 
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Benzoic acid, 4-HO- A 33 30 216 1.00 0.72 1.29 0.98 0.99 [53] 
Benzophenone, 2,2',4,4'-(HO)4- A 45 34 201 1.63 0.98 2.11 2.13 1.72 [142] 
Benzophenone, 2,3,4-(HO)3- A 45 32 141 1.02 0.76 1.97 1.84 1.66 [142] 
Benzophenone, 2,4-(HO)2- A 28 31 145 0.80 0.68 1.81 1.73 1.60 [142] 
Benzoquinone N 21 10 116 0.00 0.76 0.43 0.90 0.79 [143] 
Benzoylmandeic acid, 4- A 23 29 177 0.74 1.28 1.95 1.71 1.90 [77] 
Benzyl_benzoate N 1 11 19 0.00 0.54 1.50 1.22 1.68 [144] 
BerberineChloride B 56 27 175 0.00 1.09 2.25 2.52 2.40 [145] 
Betamethasone N -9 13 232 0.80 1.97 2.95 2.07 2.91 [99,146-148] 
Betamethasone-17-valerate (excluded**) N -29 5 184 0.56 2.04 3.20 1.97 3.63 [99,147] 
Bromhexine B 50 19 137 0.28 0.87 1.65 1.88 2.29 [149] 
Budesonide A 16 26 227 0.27 1.54 1.04 1.43 0.88 [66] 
Bupivacaine B 0 7 107 0.26 1.19 1.59 1.32 2.51 [8,140,150,151] 
Butabarbital A 24 24 127 0.52 1.21 1.36 0.98 1.66 [103] 
Butamben B 27 12 56 0.23 0.77 1.44 0.94 1.60 [31,57,70,152] 
Butamben B 51 12 58 0.23 0.77 1.44 0.94 1.60 [56] 
Caffeic acid A 42 30 196 1.35 0.93 1.57 1.27 1.29 [153] 
Caffeine N 36 20 238 0.00 1.27 1.90 1.48 1.36 [154] 
Caffeine N 39 20 238 0.00 1.27 1.90 1.48 1.36 [155] 
Camptothecin, 10-HO-(lactone) AB 52 19 268 0.00 0.00 0.00 0.00 0.00 [156] 
Camptothecin, 9-NH2-(lactone) B 36 33 212 0.40 2.27 3.74 3.12 2.53 [157] 
Carbamazepine N 24 26 192 0.39 0.92 2.06 2.12 1.81 [2,68,158-164] 
Carbenoxolone A 20 28 293 1.14 1.69 2.10 1.70 4.55 [165] 
Carboline, β- B 17 32 199 0.31 0.67 1.56 1.98 1.27 [166] 
Carvedilol B -12 20 115 0.62 2.09 3.00 3.08 3.10 [150,167-169] 
Catechol A 27 27 105 0.77 0.53 1.08 0.93 0.83 [63] 
Catechol, 3-NO2
-
 A 37 27 86 0.58 0.50 1.41 1.10 1.01 [170] 
Catechol, 4-NO2
-
 A 10 31 176 1.14 0.63 1.65 1.20 1.01 [170] 
Cefadroxil x H2O AB 8 19 197 1.55 2.82 3.48 2.76 2.49 [107-172] 
Cefatrizine.propyleneglycolate (excluded**) AB 18 26 204 2.19 3.41 4.46 3.92 3.04 [112,173] 
Cefpirone Sulfate AB 30 25 203 0.50 2.77 3.99 3.71 3.46 [174] 
Ceftazidime AB 23 18 136 1.07 3.16 4.40 3.59 3.64 [175] 
Celecoxib (excluded) AB -66 24 158 0.44 1.22 2.43 2.51 2.47 [8,176] 
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Cephalexin x H2O AB 11 24 327 1.06 2.54 3.27 2.53 2.43 [2,107,113, 177] 
Cephalosporanic acid, 7-NH2- AB 12 17 300 0.80 2.20 2.35 1.70 1.79 [178] 
Cephradine AB 10 14 140 1.06 2.59 3.06 2.45 2.48 [32,68,113] 
Chloral hydrate N 30 12 57 0.00 0.30 0.99 0.54 0.77 [179] 
Chloramphenicol N 16 16 151 0.87 1.65 2.66 1.84 2.07 [8,68,161,180] 
Chlorothiazide A 44 34 350 0.64 1.66 2.74 1.98 1.69 [181] 
Chlorpromazine (excluded) B 80 18 57 0.00 0.99 1.83 2.26 2.41 
[2,8,25,86,139,16
1, 182,184-187] 
Chlorpropamide A 44 29 128 0.59 1.13 2.38 1.46 1.90 [188] 
Chlorpropamide A 16 29 128 0.59 1.13 2.38 1.46 1.90 [8,73,186,189] 
Cholic acid A 24 28 200 1.51 1.66 2.66 1.82 3.31 [190] 
Cimetidine B -13 12 142 0.74 1.86 1.87 1.66 1.96 
[68,70,79,137, 
191] 
Cinnamic acid A 31 27 133 0.57 0.51 1.18 0.90 1.17 [192] 
Cinnamic acid, cis- (Form_I) A 22 25 42 0.57 0.51 1.18 0.90 1.17 [193] 
Cinnamic acid, cis-(Form_II) A 22 25 58 0.57 0.51 1.18 0.90 1.17 [193] 
Cinnamic acid, cis-(Form_III) A 21 25 68 0.57 0.51 1.18 0.90 1.17 [193] 
Cinnamic acid, trans- A 27 27 133 0.57 0.51 1.18 0.90 1.17 [193] 
Cinnarazine B 48 14 112 0.00 1.37 2.12 2.43 3.11 [2,162,194] 
Ciprofloxacin AB 41 21 268 0.73 1.85 2.50 2.20 2.31 [195] 
Ciprofloxacin AB 51 21 266 0.73 1.85 2.50 2.20 2.31 
[2,79,86, 104, 
196] 
Citric acid A 18 24 153 1.63 1.33 1.50 0.61 1.24 [91] 
Citric acid A 23 24 153 1.63 1.33 1.50 0.61 1.24 [197] 
Citric acid A 18 24 153 1.63 1.33 1.50 0.61 1.24 [92] 
Citric acid A 27 24 153 1.63 1.33 1.50 0.61 1.24 [43] 
Citric acid x H2O A 29 25 174 1.63 1.33 1.50 0.61 1.24 [91] 
Clartihromycin B -17 -31 218 0.80 4.49 2.97 2.32 5.91 [198] 
Clotrimazole (excluded) B -32 28 148 0.00 0.78 2.37 2.48 2.62 [199-201] 
Clozapine (excluded) B 27 18 184 0.20 1.65 1.66 2.46 2.43 [148,169,189] 
Codeine B 8 18 155 0.23 1.58 1.92 2.16 2.21 [202] 
Corticosterone N 10 13 182 0.48 1.62 2.80 1.90 2.74 
[8,68,147,203-
205] 
Cortisone N -8 16 222 0.41 1.90 3.15 2.04 2.76 [8,68,147,204] 
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Coumarin N 33 14 70 0.00 0.49 1.16 1.03 1.06 [206] 
Crotonic  acid, trans- (excluded) A 79 23 72 0.57 0.43 0.72 0.33 0.70 [207] 
Cyclacillin (anhyd.) AB -18 9 183 1.06 2.53 2.61 2.08 2.47 [208] 
Cyclacillin (excluded**) AB 0 9 183 1.06 2.53 2.61 2.08 2.47 [111,114] 
Cyclacillin x 2H2O AB 0 10 203 1.06 2.53 2.61 2.08 2.47 [208] 
Cyclobarbital A 16 26 173 0.52 1.28 1.50 1.32 1.79 [207] 
Cyclobarbital A 27 27 193 0.52 1.28 1.50 1.32 1.79 [34,110,209] 
Cyclohexanol N -9 6 25 0.31 0.32 0.53 0.42 0.90 [210] 
Cyclosporine A N -45 -40 151 1.25 7.61 #### 4.23 10.02 [67,211] 
Cyproheptadine (excluded) B 30 17 113 0.00 0.83 1.45 2.05 2.39 [2,149,150] 
Cystine, L- AB 23 13 260 1.56 2.09 1.98 1.44 1.63 [51] 
Daidzein A 66 35 330 1.16 1.27 2.23 2.21 1.79 [212] 
Danazol N -25 21 226 0.40 1.03 2.38 2.14 2.67 
[67,99,146,162, 
213, 214] 
Dapsone B 35 28 176 0.45 1.35 2.84 1.87 1.81 [32,68] 
Deferiprone A 24 20 124 0.00 0.00 0.00 0.00 0.00 [215] 
Dehydroisoandrosterone, 5, 6- N 24 14 141 0.31 1.01 2.27 1.55 2.38 [116] 
Delphinidin_chloride AB 20 33 224 2.66 1.57 2.53 3.02 2.19 [216] 
Deoxyadenosine, 2'- B 49 27 189 0.72 1.94 2.38 2.49 1.70 [217] 
Deoxycorticosterone N -28 11 142 0.17 1.32 2.55 1.69 2.68 [32,68,147] 
Deoxyguanosine AB 45 19 220 1.09 2.58 2.56 2.36 1.75 [217] 
Dexamethasone N -11 14 262 0.80 1.97 2.95 2.07 2.91 
[32,68,78,99,146, 
147,159] 
Dexamethasone N 15 14 263 0.80 1.97 2.95 2.07 2.91 [218] 
Dexamethasone N 29 14 263 0.80 1.97 2.95 2.07 2.91 [219] 
Diatrizoic acid A 11 37 300 1.28 1.18 1.97 3.36 2.50 [220] 
Diazepam B 12 21 132 0.00 1.04 1.72 2.11 2.07 
[8,67,78,140,161, 
162,189,221] 
Diazinon B -17 4 120 0.00 1.38 1.10 1.31 2.31 [222] 
Diclofenac A 20 32 168 0.70 0.67 1.95 1.81 2.03 
[2,82,102,148, 
161,223-234] 
Diflorason diacetate N 22 5 145 0.38 2.08 3.52 1.82 3.53 [235] 
Difloxacin AB 0 21 211 0.57 1.91 2.91 2.55 2.76 [104] 
Diflunisal A 22 32 214 0.70 0.44 1.50 1.55 1.63 [236] 
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Diflunisal A 37 32 214 0.70 0.44 1.50 1.55 1.63 [68,237,238] 
Digitoxin N -24 -9 256 1.27 4.02 4.20 3.46 5.69 [161,239,240] 
Diglycolic acid A 23 25 143 1.14 0.90 1.22 0.38 0.88 [43] 
Diglycolic acid A 31 25 143 1.14 0.90 1.22 0.38 0.88 [126] 
Digoxin N -34 -9 249 1.58 4.32 4.46 3.67 5.75 [8,78] 
Dimethyloxalate N 33 4 54 0.00 0.69 0.97 0.13 0.82 [241] 
Diphenylamine N 1 16 54 0.13 0.42 1.41 1.37 1.42 [242] 
Diphenylamine (excluded**) N 0 16 53 0.13 0.42 1.41 1.37 1.42 [32,243] 
Dipyridamole B 10 12 165 0.95 3.03 2.90 3.74 3.87 
[99,150,169,199, 
244-246] 
DOPA, L- AB 8 20 277 1.56 1.44 1.77 1.33 1.43 [8,110,247,248] 
Droperidol (excluded**) B -44 22 146 0.50 1.79 2.77 2.78 2.82 [169,249] 
Enoxacin AB 24 17 222 0.73 1.96 2.45 2.06 2.23 [104] 
Ergotamine (excluded**) B 18 24 213 0.79 3.69 4.60 4.56 4.21 [140,188,250] 
Erythromycin B -23 -31 191 1.05 4.63 3.04 2.51 5.77 [86,198,251] 
Erythromycin B -18 -31 191 1.05 4.63 3.04 2.51 5.77 [198] 
Estradiol, 17-β A 52 32 176 0.81 0.95 2.30 1.85 2.20 [252] 
Estrone A 37 34 255 0.50 0.95 2.53 1.85 2.16 [8,68,161,253] 
Ethinylestradiol, 17α- A 37 32 144 0.90 1.02 2.43 2.07 2.40 
[2,32,68, 253, 
254] 
Ethisterone N 28 19 269 0.40 1.08 2.40 1.78 2.58 [252] 
Ethylmalonic acid A 8 25 114 1.14 0.72 1.05 0.35 0.96 [255] 
Etoricoxib (excluded**) B 13 26 128 0.00 1.41 2.77 2.60 2.54 [256,257] 
Etoxadrol (excluded) B 113 8 124 0.15 1.05 1.24 1.20 2.13 [258] 
Eucalyptol N -23 1 37 0.00 0.32 0.39 0.43 1.36 [259] 
Ezetimibe (excluded) A -97 30 165 0.81 1.77 2.61 2.65 2.94 [260,261] 
Famotidine (excluded) B -60 14 164 1.21 2.78 2.24 2.69 2.26 
[223,248,262, 
263] 
Felodipine B 23 8 145 0.13 1.42 1.85 1.56 2.71 [99,264,265] 
Fenbufen A 41 31 186 0.57 0.85 2.05 1.79 1.98 [266] 
Fenofibrate (excluded) N -49 7 81 0.00 1.13 2.11 1.62 2.72 [60,160,267,268] 
Fentiazac AB 9 30 161 0.57 0.81 2.29 2.62 2.29 [102] 
Ferulic acid A 36 28 169 0.85 0.87 1.46 1.11 1.43 [153] 
Fleroxacin AB 12 12 184 0.57 1.81 2.37 1.81 2.45 [104] 
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Fluconazole B 27 24 139 0.31 1.42 2.45 2.16 2.01 [269-272] 
Flufenamic acid A 29 28 125 0.72 0.59 1.36 1.26 1.83 
[8,68,139,186, 
226, 227,273-275] 
Fluorene (excluded**) N 4 22 117 0.00 0.19 1.13 1.65 1.36 [31,161] 
Fluotrimazole (excluded**) B 1 23 132 0.00 0.66 2.14 2.15 2.65 [32,34] 
Fluphenazine B 16 11 142 0.23 1.80 2.00 2.40 3.09 [8,25] 




Flurbiprofen A 43 28 111 0.57 0.58 1.51 1.50 1.84 [236] 
Folic acid (excluded) AB 76 19 250 1.95 3.14 3.74 3.24 3.04 [279] 
Fumaric acid A 32 30 287 1.14 0.75 1.16 0.50 0.78 [63] 
Furo[3,4-b]quinolin-3(1H)-one, 9-HO-1,7-Me2- AB 24 23 200 0.13 1.07 1.65 1.90 1.63 [38] 
Furosemide A 23 31 238 1.25 1.50 2.37 2.07 2.10 [66] 
Furosemide A 37 31 238 1.25 1.50 2.37 2.07 2.10 
[2,8,73,148,185, 
223,280-284] 
Gallic acid A 43 32 251 1.66 1.01 1.64 1.29 1.11 [286] 
Gallic acid A 45 32 251 1.66 1.01 1.64 1.29 1.11 [287] 
Genistein A 35 35 302 1.30 1.20 2.25 2.36 1.85 [212] 
Glibenclamide (excluded) A -40 32 170 0.85 2.01 3.84 2.64 3.56 
[99,158,161,162, 
189,199,288-290] 
Gliclazide AB 4 17 181 0.59 1.66 2.54 1.93 2.36 [189,289,291] 
Glimepiride (excluded**) A 16 31 207 0.75 2.15 3.50 2.41 3.72 [260,292] 
Glipizide AB -14 18 209 0.85 2.19 3.71 2.52 3.30 
[160,162,227, 
268] 
Glucoside, α-D-Me- N 4 8 168 1.00 1.83 1.50 1.19 1.34 [293] 
Glutamic acid, D- AB 26 11 199 1.35 1.26 1.37 0.55 1.06 [51] 
Glutamic acid, DL- AB 26 11 201 1.35 1.26 1.37 0.55 1.06 [51] 
Glutamic acid, DL- AB 27 11 201 1.35 1.26 1.37 0.55 1.06 [45] 
Glutamic acid, L- AB 27 11 201 1.35 1.26 1.37 0.55 1.06 [51] 
Glutamic acid, L- AB 30 11 201 1.35 1.26 1.37 0.55 1.06 [54] 
Glutaric acid A 25 25 97 1.14 0.69 1.07 0.34 0.96 [29] 
Glutaric acid A 26 25 97 1.14 0.69 1.07 0.34 0.96 [43] 
Glutaric acid A 31 25 97 1.14 0.69 1.07 0.34 0.96 [44] 
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Glutethimide A 41 25 84 0.34 1.02 1.40 1.31 1.73 [294] 
Glutethimide A 21 25 84 0.34 1.02 1.40 1.31 1.73 [295] 
Glutethimide x H2O A 49 25 84 0.34 1.02 1.40 1.31 1.73 [294] 
Glycine AB 14 16 240 0.78 0.90 0.93 0.37 0.57 [51] 
Glycine AB 12 16 245 0.78 0.90 0.93 0.37 0.57 [63] 
Glycine AB 18 17 262 0.78 0.90 0.93 0.37 0.57 [94,97,296-299] 
Glycolic acid A 2 23 77 0.74 0.63 0.67 0.30 0.52 [126] 
Glycolic acid A 11 23 77 0.74 0.63 0.67 0.30 0.52 [126] 
Griseofulvin N 4 13 220 0.00 1.53 2.26 1.74 2.44 [188] 
Griseofulvin N 28 13 220 0.00 1.53 2.26 1.74 2.44 
[32,67,68,79,99, 
199,300] 
Griseofulvin N 35 14 220 0.00 1.58 2.32 1.86 2.40 [295] 
Haloperidol B 42 13 149 0.31 1.45 2.08 2.00 2.80 
[68,139,150,194, 
301] 
Hemimellitic acid A 44 30 200 1.71 1.10 1.84 1.14 1.36 [131] 
Heptabarbital A 23 26 174 0.52 1.28 1.50 1.32 1.93 [103] 
Hexaglycine (excluded**) AB 16 10 141 2.06 3.71 5.32 1.91 2.55 [247,299] 
Hexobarbital A 30 26 147 0.24 1.33 1.50 1.34 1.79 [8,186] 
Hexobarbital A 35 26 146 0.24 1.33 1.50 1.34 1.79 [130] 
Hippuric acid A 30 29 187 0.83 1.01 1.95 1.06 1.33 [302] 
Histidine, L- AB 13 24 282 0.35 0.82 1.56 1.07 1.13 [51] 
Hydrastine (excluded**) B 2 16 132 0.00 1.89 2.60 2.33 2.68 [32,34] 
Hydrobenzoin (excluded**) N 0 14 138 0.54 1.09 1.47 1.61 1.72 [32,70] 
Hydrochlorothiazide A 12 32 274 1.01 1.76 2.77 2.15 1.73 
[32,68,79,160,162 
163,223,280] 
Hydrochlorothiazide A 33 32 274 1.01 1.76 2.77 2.15 1.73 [181] 
Hydrochlorothiazide A 40 32 274 1.01 1.76 2.77 2.15 1.73 [303] 
Hydrocortisone N -6 14 219 0.73 1.90 2.92 2.04 2.80 
[32,68,146,147, 
148,159,163] 
Hydrocortisone N 20 14 219 0.73 1.90 2.92 2.04 2.80 [219] 
Hydroquinone A 20 29 174 1.00 0.65 1.14 1.02 0.83 [63] 
Hydroxyprogesterone, 17-α N 30 14 222 0.17 1.32 2.50 1.66 2.68 [252] 
Hydroxyproline, L- AB 6 16 272 0.95 1.20 1.08 0.77 0.94 [51] 
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Ibuprofen, (+)- A 24 24 76 0.57 0.51 1.01 0.78 1.78 [236] 
Ibuprofen, (±)- A 29 24 76 0.57 0.51 1.01 0.78 1.78 [236] 
Indapamide A 14 32 161 0.70 1.86 3.20 2.64 2.50 [68,239,308] 
Indinavir (excluded**) B -23 6 168 0.98 3.59 4.27 3.63 4.90 [309,310] 




Iopamidol (anhyd.) N -5 24 189 2.20 3.48 4.72 4.41 3.68 [317] 
Iopamidol x 5H2O N 56 24 189 2.20 3.48 4.72 4.41 3.68 [317] 
Iopamidol x H2O N 9 24 189 2.20 3.48 4.72 4.41 3.68 [317] 
Isoamylmalonic acid A 11 25 111 1.14 0.76 1.05 0.35 1.39 [255] 
Isoguanine (excluded**) AB -6 24 360 0.60 1.80 1.40 1.62 0.98 [33,247] 
Isoleucine, D- AB 3 11 265 0.78 0.97 0.92 0.39 1.13 [51] 
Isoleucine, DL- AB 8 12 280 0.78 0.97 0.92 0.39 1.13 [51] 
Isoleucine, L- AB 4 12 280 0.78 0.97 0.92 0.39 1.13 [51] 
Isoniazid (excluded**) B 0 21 171 0.47 1.39 1.85 1.19 1.03 [248,318] 
Isophthalic acid A 34 33 347 1.14 0.77 1.46 0.94 1.15 [43] 
Isophthalic acid A 48 33 345 1.14 0.77 1.46 0.94 1.15 [319] 
Isophthalic acid A 66 33 347 1.14 0.77 1.46 0.94 1.15 [131] 
Itaconic acid A 34 27 175 1.14 0.76 1.07 0.44 0.92 [45] 
Ivermectin N -25 -32 140 0.68 4.23 3.21 3.24 6.72 [101,300,320] 
Ketoconazole B 10 21 146 0.00 2.22 3.76 3.14 3.72 
[146,161,162,169, 
205,321-323] 




Ketoprofen A 34 28 94 0.57 0.87 1.97 1.56 1.98 [236] 
Lactose N 16 4 202 2.01 3.40 2.69 2.33 2.23 [197] 
Lamotrigine B 66 35 217 0.45 0.93 2.13 2.40 1.65 [325-328] 
Leucine, DL- AB 9 12 293 0.78 0.97 0.92 0.39 1.13 [51] 
Leucine, L- AB 3 12 293 0.78 0.97 0.92 0.39 1.13 [51] 
Levulinic acid A 27 22 31 0.57 0.67 1.12 0.38 0.90 [43] 
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Levulinic acid A 43 22 31 0.57 0.67 1.12 0.38 0.90 [126] 
Lidocaine B -9 6 69 0.26 1.17 1.50 1.10 2.06 [329] 
Lidocaine B -9 6 69 0.26 1.17 1.50 1.10 2.06 [330] 
Lidocaine B -4 6 69 0.26 1.17 1.50 1.10 2.06 
[32,82,110,150, 
203,305,331] 
Lomefloxacin AB 10 15 240 0.73 1.81 2.37 1.87 2.43 [104] 
Loratidine (excluded**) B -29 17 135 0.00 1.14 2.09 2.19 2.87 [169,322] 
Lysine, D- AB -15 8 217 0.99 1.48 1.26 0.58 1.23 [51] 
Madelic acid, D- A 60 25 132 0.74 0.89 1.05 0.90 1.13 [77] 
Maleic acid A 19 26 134 1.14 0.75 1.16 0.50 0.78 [197] 
Maleic acid A 21 26 134 1.14 0.75 1.16 0.50 0.78 [91] 
Maleic acid A 24 26 134 1.14 0.75 1.16 0.50 0.78 [92] 
Malic acid A 22 24 131 1.14 0.99 1.10 0.47 0.88 [91] 
Malic acid A 12 24 131 1.14 0.99 1.10 0.47 0.88 [43] 
Malic acid A 13 24 131 1.14 0.99 1.10 0.47 0.88 [92] 
Malonic acid A 4 26 135 1.14 0.69 1.06 0.34 0.68 [333] 
Malonic acid A 9 26 136 1.14 0.69 1.06 0.34 0.68 [43] 
Malonic acid A 12 26 136 1.14 0.69 1.06 0.34 0.68 [92] 
Malonic acid, n-Buthyl- A 21 25 102 1.14 0.73 1.06 0.34 1.24 [255] 
Malonic acid, n-Propyl- A 10 25 114 1.14 0.72 1.06 0.35 1.10 [255] 
Mannitol N 19 10 167 1.62 1.81 1.75 1.23 1.31 [63] 
Mebendazole (excluded**) AB 37 32 289 0.71 1.38 2.76 2.45 2.13 [334,335] 
Meclofenamic acid A 13 33 257 0.65 0.62 1.68 1.87 2.03 [139,226,246] 
Mefenamic acid (excluded) A 48 31 231 0.65 0.70 1.47 1.65 1.92 [205] 
Mellitic acid A 4 22 287 3.43 2.08 2.99 1.71 2.01 [131] 
Mellophanic acid A 33 28 212 2.29 1.43 2.22 1.33 1.58 [131] 
Meloxicam (excluded) AB -43 27 254 0.72 2.02 3.12 2.60 2.32 [336] 
Menthol N 0 1 43 0.31 0.42 0.50 0.44 1.47 [197] 
Mepivacaine, DL- B -12 12 150 0.26 1.18 1.58 1.32 2.09 [330] 
Meprobamate N 41 5 104 0.89 1.12 1.62 0.71 1.73 [337] 
Meprobamate N 42 5 104 0.89 1.12 1.62 0.71 1.73 [337] 
Mesalamine AB 18 27 280 0.93 0.70 1.52 1.22 1.09 [338] 
Methionine, DL- AB 18 15 281 0.78 1.06 1.08 0.72 1.15 [51] 
Methionine, L- AB 12 15 278 0.78 1.06 1.08 0.72 1.15 [51] 
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Methylmalonic acid A 10 26 130 1.14 0.72 1.05 0.35 0.82 [255] 
Methylprednisolone (Form II) N 21 15 233 0.73 2.00 3.00 2.20 2.90 [339] 
Metiazinic acid (excluded) A 95 31 144 0.57 0.89 1.93 2.16 1.98 [8] 
Metolazone A 30 34 256 0.59 1.74 2.86 2.69 2.50 [340] 
Metronidazole B 6 22 159 0.31 0.86 1.75 1.12 1.19 
[32,34,68,183, 
341] 
Morphine AB -1 21 254 0.50 1.47 1.59 2.23 2.07 [305,342,343] 
m-toluic acid (excluded) A 71 26 110 0.57 0.44 1.02 0.77 1.07 [53] 
N-(2,3-dichlorophenyl)benzenesulfonamide A 28 31 114 0.43 0.74 2.21 1.90 1.95 [134] 
N-(2-chlorophenyl)benzenesulfonamide A 13 30 125 0.36 0.81 2.14 1.79 1.83 [134] 
N-(4-chlorophenyl)benzenesulfonamide A 39 30 122 0.42 0.81 2.17 1.82 1.83 [134] 
N,2-dimethylpropanamide N -16 6 62 0.26 0.62 1.04 0.32 0.93 [41] 
N-acetyl-L-phenylalanine, Ethyl ester N 20 7 85 0.26 1.05 1.91 0.95 1.89 [344] 
Nalidixic acid AB -19 20 230 0.57 1.34 1.94 1.63 1.70 
[68,104,161,248, 
365] 
Naphthoic acid, 2- A 54 30 185 0.57 0.50 1.40 1.47 1.30 [345] 
Naphthol, 1- A 25 28 96 0.50 0.45 1.23 1.50 1.14 [346] 
Naphthol, 2- A 26 28 121 0.50 0.45 1.23 1.50 1.14 [347] 
Naphthylamine-1-sulfonic acid, 2- AB 22 27 180 0.54 1.25 2.49 1.87 1.53 [136] 
Naphthylamine-5-sulfonic acid, 1- AB 25 32 300 0.54 1.25 2.52 1.89 1.53 [136] 
Naproxen A 28 29 153 0.57 0.75 1.49 1.54 1.78 [236] 
Naringin A 26 11 83 2.10 3.86 4.09 3.97 3.89 [248,348] 
N-butylacetamide N -15 5 55 0.26 0.60 1.06 0.31 1.07 [41] 
Nevirapine B -6 31 248 0.42 1.37 2.29 2.36 1.95 [349] 
Nicotinic acid AB 14 20 237 0.57 0.73 1.21 0.79 0.89 [43] 
Nicotinic acid AB 20 20 237 0.57 0.73 1.21 0.79 0.89 [8,350] 
Nifedipine B 42 13 173 0.13 1.53 2.25 1.56 2.50 
[162,239,265,351, 
352] 
Niflumic acid AB 29 18 204 0.72 0.77 1.42 1.33 1.79 
[185,226,273,283, 
353] 
N-isopropylacetamide N -17 6 66 0.26 0.62 1.04 0.32 0.93 [41] 
Nitrendipine B 45 11 158 0.13 1.54 2.26 1.56 2.64 [205,265,300] 
Nitroaminoguanidine (excluded) B 112 15 185 0.69 1.69 1.18 1.06 0.78 [354] 
Nitrofurantoin A 32 31 268 0.24 1.34 2.03 1.65 1.45 
[68,78,139,185,18
6, 280,355] 
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Nitrofurantoin A 44 31 268 0.24 1.34 2.03 1.65 1.45 [356] 
Nitroglycerin N 7 11 14 0.00 0.45 1.87 0.58 1.23 [357] 
N-methylacetamide N -13 8 28 0.26 0.59 1.05 0.32 0.65 [62] 
N-methylacetamide N -4 8 28 0.26 0.59 1.05 0.32 0.65 [41] 
N-methylpivalamide N -6 5 91 0.26 0.63 0.99 0.29 1.07 [41] 
N-octylacetamide N -5 0 60 0.26 0.61 1.08 0.30 1.63 [41] 
Norethindone N 22 19 203 0.40 1.07 2.44 1.81 2.44 [358] 
Norethindone acetate N 30 13 161 0.09 1.13 2.58 1.66 2.74 [358] 
Norfloxacin AB 19 17 221 0.73 1.84 2.43 1.98 2.27 [2,68,104,148] 
Norfloxacin AB 26 17 215 0.73 1.84 2.43 1.98 2.27 [195] 
Norleucine, DL- AB 11 13 299 0.78 0.94 0.94 0.38 1.13 [51] 
Noscapine B 44 18 176 0.00 2.09 3.09 2.39 2.88 [8] 
N-propylacetamide N -16 6 57 0.26 0.60 1.06 0.31 0.93 [41] 
N-tert-butylacetamide N -3 6 97 0.26 0.63 0.99 0.29 1.07 [41] 
Ofloxacin AB 4 18 254 0.57 2.05 2.58 2.26 2.50 [104] 
Olmesartan Medoxomil (excluded**) AB -60 19 181 0.95 2.61 3.72 3.77 4.04 [359,360] 
Oxalic acid A 9 27 190 1.14 0.68 1.06 0.34 0.54 [91] 
Oxalic acid A 26 27 190 1.14 0.68 1.06 0.34 0.54 [43] 
Oxalic acid A 34 27 190 1.14 0.68 1.06 0.34 0.54 [92] 
Oxalic acid x 2H2O A 35 25 102 1.14 0.68 1.06 0.34 0.54 [91] 
Oxazepam B 6 25 206 0.64 1.29 1.75 2.23 1.99 [67,203,361] 
Oxyphenbutazone A 52 28 96 0.50 1.89 2.69 2.38 2.49 [32,82,273] 
Papaverine B -8 21 147 0.00 1.47 2.76 2.19 2.59 
[139,169,186,283, 
362,363,365,366] 
Paraben, Buthyl- A 30 25 69 0.66 0.73 1.26 0.87 1.55 [65] 
Paraben, Buthyl- A 41 25 69 0.66 0.73 1.26 0.87 1.55 
[8,31,57,68, 331, 
367] 
Paraben, Ethyl- A 29 27 117 0.66 0.69 1.33 1.15 1.25 [65] 
Paraben, Methyl- A 21 26 131 0.66 0.72 1.24 0.87 1.13 
[31,32,57,68,70, 
331,367] 
Paraben, Methyl- A 28 27 131 0.66 0.68 1.32 1.15 1.11 [65] 
Paraben, Propyl- A 34 27 97 0.66 0.69 1.33 1.15 1.39 [65] 
Paraben, Propyl- A 44 25 97 0.66 0.73 1.25 0.87 1.41 
[8,31,57,68,70,17
1, 331,367] 
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Pentachlorophenol A 22 32 179 0.70 0.00 1.13 1.27 1.39 [39,368] 
Pentazocine (excluded**) AB 19 7 146 0.50 1.04 1.13 1.54 2.45 [67,369] 
Pentobarbital A 23 24 130 0.52 1.24 1.35 0.98 1.80 [103] 
Perphenazine B 14 16 97 0.23 1.84 2.33 2.87 3.02 [8,25,68,182,189] 
Phenanthroline, 1,10- B 28 28 115 0.00 0.67 1.51 2.07 1.37 [370] 
Phenazine-1-carboxylic  acid AB 14 31 239 0.57 0.94 1.85 2.26 1.59 [371] 
Phenazopyridine B 37 24 139 0.45 1.09 1.67 2.03 1.64 
[149,224,372, 
373] 
Phenobartibal A 18 28 176 0.52 1.29 1.81 1.56 1.70 [374] 
Phenobartibal A 24 28 176 0.52 1.29 1.81 1.56 1.70 [374] 
Phenol A 11 24 41 0.50 0.39 0.90 0.78 0.78 [197] 
Phenol A 13 24 41 0.50 0.39 0.90 0.78 0.78 [59] 
Phenol, 2-NH2- AB 6 22 172 0.51 0.55 1.21 1.05 0.88 [63] 
Phenol, 2-NO2- A 29 24 44 0.11 0.35 1.24 0.96 0.95 [170] 
Phenol, 3-NH2- AB 24 20 125 0.73 0.65 1.28 1.07 0.88 [63] 
Phenol, 3-NO2- A 17 28 97 0.69 0.49 1.47 1.05 0.95 [170] 
Phenol, 4-NH2- AB 14 23 190 0.73 0.69 1.32 1.09 0.88 [63] 
Phenol, 4-NO2- A 29 28 113 0.67 0.49 1.47 1.05 0.95 [170] 
Phenol, 4-t-Bu- A 20 25 100 0.50 0.43 0.79 0.79 1.34 [375] 
Phenothiazine N 24 27 185 0.13 0.50 1.53 1.95 1.48 [376] 
Phenothiazine N 38 27 185 0.13 0.50 1.53 1.95 1.48 [377] 
Phenylacetic  acid (excluded**) A 10 25 77 0.57 0.45 1.08 0.75 1.07 [34,378] 
Phenylalanine, DL- AB 12 15 186 0.78 1.02 1.39 0.95 1.31 [51] 
Phenylalanine, L- AB 11 15 186 0.78 1.02 1.39 0.95 1.31 [51] 
Phenylalanine, L- AB 17 15 186 0.78 1.02 1.39 0.95 1.31 [94,296,379] 





Phthalic acid, 2- A 20 30 210 1.14 0.77 1.46 0.94 1.15 [197] 
Phthalic acid, 2- A 32 30 230 1.14 0.77 1.46 0.94 1.15 [63] 
Phthalic acid, 2- A 32 30 210 1.14 0.77 1.46 0.94 1.15 
[32,44,131,139, 
185] 
Phthalic acid, 2- A 35 30 210 1.14 0.77 1.46 0.94 1.15 [43] 
Picric acid A 30 29 122 0.02 0.46 2.22 1.43 1.30 [197] 
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Pimelic acid A 36 25 105 1.14 0.70 1.08 0.33 1.24 [44] 
Pimelic acid A 42 25 105 1.14 0.70 1.08 0.33 1.24 [43] 
Pipemidic acid AB 5 19 254 0.73 2.07 2.48 2.20 2.17 [8] 




Prednisolone N 17 17 239 0.73 1.97 3.02 2.19 2.76 [188] 
Prednisolone N 17 17 239 0.73 1.97 3.02 2.19 2.76 
[31,32,68,147, 
162, 386] 
Prehnitic acid A 17 28 211 2.29 1.43 2.22 1.33 1.58 [131] 
Progesterone N 2 12 126 0.00 1.04 2.49 1.56 2.62 
[8,68,147,148, 
159, 161,199,204] 
Proline, DL- AB 7 14 208 0.71 0.81 0.87 0.54 0.88 [121] 
Proline, L- AB 3 15 228 0.71 0.81 0.87 0.54 0.88 [387] 
Proline, L- AB 5 14 221 0.71 0.81 0.87 0.54 0.88 [51] 
Promazine B 23 16 33 0.00 1.06 1.74 2.13 2.28 [8,25,182] 
Propionyl-r-mandelic acid A 33 26 126 0.57 0.81 1.47 0.82 1.57 [77] 
Propylphenazone B 0 12 103 0.00 1.33 1.69 1.40 1.91 [119] 
Prostaglandin E2 A 13 23 67 1.20 1.48 1.95 1.32 2.94 [388] 
Prostaglandin F2α (excluded**) A 4 22 30 1.51 1.48 1.72 1.32 2.98 [31,389] 
p-toluic acid A 24 28 184 0.57 0.44 1.02 0.77 1.07 [54] 
p-toluic acid A 43 28 184 0.57 0.44 1.02 0.77 1.07 [53] 
Puararin A 22 22 189 0.00 0.00 0.00 0.00 0.00 [390] 
Pyrazinamide B -11 24 190 0.49 1.04 1.68 1.07 0.89 [68,70,391] 
Pyrene N 42 33 152 0.00 0.25 1.52 2.60 1.59 [118] 
Pyromellitic  acid A 50 30 278 2.29 1.43 2.22 1.33 1.58 [131] 
Quetiapine (excluded**) B -31 14 163 0.23 2.01 1.93 2.72 2.91 [171,363] 
Quinoline, 8-HO- AB 27 20 76 0.07 0.73 1.36 1.55 1.10 [392] 
Quinoline,1,2,3,4-tetrahydro- B 11 15 16 0.13 0.39 0.94 1.01 1.13 [393] 
Resorcinol A 10 27 110 1.00 0.61 1.10 0.99 0.83 [63] 
Resveratrol, trans- A 30 33 254 1.50 1.04 1.82 1.97 1.74 [394] 
Rifampicin AB -9 -8 164 2.55 4.66 4.67 4.73 6.21 [395-398] 
Risocaine B 31 14 76 0.23 0.77 1.43 0.94 1.45 [55] 
Risocaine (excluded**) B 18 14 74 0.23 0.77 1.43 0.94 1.45 [55] 
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Ritonavir B 21 10 168 0.88 3.14 5.05 3.69 5.55 [188] 
Rofecoxib N -15 18 207 0.00 1.15 2.43 1.66 2.23 [8,176,399] 
Rosiglitazone (excluded**) AB 80 17 123 0.34 1.88 2.64 2.55 2.61 [400,401] 
Salbutamol AB 0 4 151 1.19 1.82 1.26 1.43 1.98 [402] 
Salicylamide A 37 29 140 0.62 0.61 1.57 1.16 1.03 [403] 
Salicylic acid A 24 28 158 0.70 0.40 1.10 0.91 0.99 [43] 
Salicylic acid A 25 28 158 0.70 0.40 1.10 0.91 0.99 
[32,34,44,68,71, 
82, 140,404] 
Saquinavir (excluded) B -22 19 350 1.46 3.89 5.55 4.09 5.30 [163,310] 
Secbumetone B 0 9 86 0.26 1.16 1.28 1.19 1.84 [405] 
Secobarbital A 30 24 98 0.52 1.30 1.41 1.11 1.90 [103] 
Serine, D- AB 15 13 220 1.03 1.30 1.15 0.60 0.76 [121] 
Serine, DL- AB 21 14 240 1.03 1.30 1.15 0.60 0.76 [51] 
Serine, DL- AB 23 14 240 1.03 1.30 1.15 0.60 0.76 [121] 
Serine, L- AB 12 13 222 1.03 1.30 1.15 0.60 0.76 [51] 
Serine, L- AB 16 14 246 1.03 1.30 1.15 0.60 0.76 [96,97] 
Serine, L- AB 38 13 220 1.03 1.30 1.15 0.60 0.76 [98] 
Serine x H2O, L- AB 16 12 222 1.34 1.58 1.38 0.70 0.93 [51] 
Silybin A 33 28 174 1.39 2.58 3.57 3.57 3.25 [406] 
Spironolactone N 3 18 135 0.00 1.63 3.81 2.24 3.17 
[32,68,148,161, 
300] 
Stavudine A 19 27 160 0.47 1.65 1.96 1.55 1.56 [407] 
Strychnine B 29 25 275 0.00 1.68 1.99 2.62 2.41 [408] 
Suberic acid A 27 26 142 1.14 0.70 1.08 0.33 1.39 [126] 
Suberic acid A 35 26 142 1.14 0.70 1.08 0.33 1.39 [43] 
Succinic acid A 29 27 187 0.97 0.69 1.06 0.34 0.82 [91] 
Succinic acid A 29 27 187 0.97 0.69 1.06 0.34 0.82 [29] 
Succinic acid A 29 27 187 0.97 0.69 1.06 0.34 0.82 [92] 
Succinic acid A 29 27 187 0.97 0.69 1.06 0.34 0.82 [43] 
Succinimide A 30 24 126 0.34 0.89 0.99 0.76 0.70 [63] 
Succinyl_sulfathiazole AB 14 25 194 1.34 1.78 3.39 2.25 2.34 [294] 
Succinyl_sulfathiazole.H2O(I) AB 50 25 194 1.34 1.78 3.39 2.25 2.34 [294] 
Succinyl_sulfathiazole.H2O(II) AB 46 25 194 1.34 1.78 3.39 2.25 2.34 [294] 
Sucrose N 6 3 188 2.01 3.43 2.63 2.32 2.23 [197] 
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Sucrose N 1 2 191 2.01 3.43 2.63 2.32 2.23 [409] 
Sulfadiazine AB 38 29 253 0.59 1.40 2.58 2.08 1.72 [61,68,410-416] 
Sulfadimethoxine (excluded) AB -56 22 204 0.59 1.78 2.77 2.17 2.12 [8,171] 
Sulfamerazine AB 41 27 237 0.59 1.41 2.52 2.10 1.86 
[68,139,246,411, 
415,417] 
Sulfamethazine AB 48 23 176 0.59 1.41 2.46 2.13 2.00 [68,70,415,418] 
Sulfamethizole AB 27 30 208 0.59 1.26 2.71 2.17 1.79 [8,246] 
Sulfamethoxazole AB 27 26 167 0.59 1.21 2.43 1.99 1.72 [8,68,73,140] 
Sulfanilacetamide AB 12 24 183 0.71 1.31 2.63 1.51 1.49 [8] 
Sulfanilamide AB 44 22 165 0.67 1.18 1.96 1.46 1.20 [419] 
Sulfanilamide x H2O AB 45 23 185 0.67 1.18 1.96 1.46 1.20 [420] 
Sulfapyridine (excluded) AB 38 27 192 0.59 1.32 2.54 2.04 1.76 [421] 
Sulfasalazine AB 10 26 220 1.06 2.21 3.42 3.00 2.70 [139,162,186,205] 
Sulfathiazole AB 18 29 202 0.59 1.21 2.60 2.06 1.69 
[8,68,73,139,186, 
411,422,423] 
Sulfathiazole (Form α) AB 42 29 202 0.59 1.21 2.60 2.06 1.69 [424] 
Sulfathiazole (Form β) AB 36 29 202 0.59 1.21 2.60 2.06 1.69 [424] 
Sulfisomidine AB 13 26 243 0.59 1.44 2.49 2.12 2.00 [32,415,418] 
Sulindac A 39 32 184 0.57 1.39 2.72 2.26 2.57 [425] 
Tartaric acid A 16 24 175 1.23 1.30 1.13 0.61 0.94 [91] 
Tartaric acid A 7 24 175 1.23 1.30 1.13 0.61 0.94 [43] 
Tartaric acid A 10 24 175 1.23 1.30 1.13 0.61 0.94 [92] 
Taurine AB 25 18 300 0.52 1.34 1.64 0.49 0.83 [51] 
Taurine AB 22 17 328 0.52 1.34 1.64 0.49 0.83 [63] 
t-butanol N 4 4 26 0.31 0.35 0.39 0.19 0.73 [426] 
Temafloxacin AB 58 18 175 0.73 1.81 2.87 2.39 2.77 [104] 
Terephthalic acid A -7 32 300 1.14 0.77 1.46 0.94 1.15 [43] 
Terephthalic acid A 1 32 300 1.14 0.77 1.46 0.94 1.15 [131] 




Testosterone N 23 14 155 0.31 1.01 2.27 1.55 2.38 [219] 
Testosterone Propionate (excluded**) N 15 8 120 0.00 1.07 2.40 1.41 2.82 [32,99] 
Thalidomide A 18 32 275 0.34 1.72 2.53 2.01 1.75 [427] 
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Thalidomide, N-Me- N 32 18 159 0.00 1.77 2.55 2.03 1.89 [427] 
Thalidomide, N-Pn- N 35 11 105 0.00 1.79 2.56 2.02 2.45 [427] 
Thalidomide, N-Pr- N 4 15 136 0.00 1.78 2.55 2.03 2.17 [427] 
Theophylline A 31 31 272 0.35 1.29 1.99 1.46 1.22 [294] 
Theophylline A 13 31 273 0.35 1.29 1.99 1.46 1.22 
[8,33,68,70,86, 
224, 305,404,428] 
Theophylline x H2O A 45 30 272 0.66 1.58 2.21 1.56 1.39 [294] 
Thiopental A 36 28 158 0.51 1.34 2.00 1.49 1.90 [429] 
Threonine, L- AB 10 14 270 1.03 1.33 1.14 0.61 0.91 [98] 
Threonine, L- AB 12 13 256 1.03 1.33 1.14 0.61 0.91 [32,97] 
Thymol A 16 24 50 0.50 0.42 0.78 0.84 1.34 [207] 
Thymol (excluded**) A 10 24 52 0.50 0.42 0.78 0.84 1.34 [32,139] 
Tolbutamide A 17 28 129 0.59 1.15 2.21 1.33 2.06 
[8,246,401,430, 
431] 
Toluenesulfonic acid, 2-, x 2H2O A 5 28 199 0.31 0.88 1.72 0.89 1.20 [432] 
Toluenesulfonic acid, 2-, x H2O A -1 27 179 0.31 0.88 1.72 0.89 1.20 [432] 
Toluenesulfonic acid, 4-, x H2O A 5 26 125 0.31 0.88 1.72 0.89 1.20 [432] 
Triamcinolone N 20 16 270 1.03 2.25 3.21 2.27 2.83 [68,147,148,213] 
Triamcinolone acetonide N 15 14 293 0.56 2.14 3.13 2.18 3.15 [433] 
Triamterene B 16 44 313 0.68 1.45 2.64 3.19 1.83 [68,434] 
Trifluoperazine B 22 8 25 0.00 1.42 1.79 2.17 2.89 [25,182,435] 
Triflupromazine (excluded) B 120 10 25 0.00 0.94 1.51 1.79 2.48 [25,182,187] 
Trimellitic acid A 34 30 219 1.71 1.10 1.84 1.14 1.36 [131] 
Trimesic acid A 46 34 375 1.71 1.10 1.84 1.14 1.36 [131] 
Tris(hydroxymethyl)aminomethane B 17 11 172 1.01 1.62 1.16 0.82 0.95 [436] 
Tryptophan, (S)-(-)- AB 12 24 283 1.09 1.23 1.80 1.62 1.54 [98] 
Tryptophan, DL- AB 18 24 289 1.09 1.23 1.80 1.62 1.54 [437] 
Tryptophan, L- AB 11 24 283 1.09 1.23 1.80 1.62 1.54 [51] 
Tyrosine AB 19 22 343 1.28 1.29 1.60 1.18 1.37 [32,37,438-440] 
Tyrosine, D- AB 27 20 312 1.28 1.29 1.60 1.18 1.37 [387] 
Tyrosine, DL- AB 25 26 325 0.50 0.70 1.42 1.24 1.37 [51] 
Tyrosine, DL- AB 26 26 325 0.50 0.70 1.42 1.24 1.37 [37] 
Tyrosine, DL- AB 28 21 325 0.50 0.70 1.42 1.24 1.37 [387] 
Tyrosine, L- AB 23 22 319 1.28 1.29 1.60 1.18 1.37 [80] 
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Tyrosine, L- AB 25 20 319 1.28 1.29 1.60 1.18 1.37 [51] 
Urea N 12 17 133 0.72 0.69 1.17 0.63 0.47 [115] 
Urea N 15 17 133 0.72 0.69 1.17 0.63 0.47 [197] 
Uric acid A 27 31 300 0.80 1.58 2.36 1.48 1.00 [285] 
Uric acid x 2H2O A 42 32 320 0.80 1.58 2.36 1.48 1.00 [109] 
Ursocholic acid A 4 27 157 1.51 1.66 2.66 1.82 3.31 [190] 
Valine, D- AB 2 14 295 0.78 0.97 0.92 0.39 0.99 [51] 
Valine, DL- AB 7 14 296 0.78 0.97 0.92 0.39 0.99 [51] 
Valine, L- AB 4 14 311 0.78 0.97 0.92 0.39 0.99 [51] 
Vanillin A 22 25 82 0.44 0.76 1.46 1.02 1.13 [197] 
Vidarabine B 43 29 234 0.97 2.22 2.64 2.69 1.75 [69] 
Xanthine A 47 32 300 0.89 1.14 1.75 1.47 0.94 [8,68] 
a
 Compound names: underlined = calorimetric data; italic = excluded data; double asterisk = "n=2, different labs" data (see text). 
b
 A = acid, B = base, AB = ampholyte/zwitterion, N = nonionizable molecule. 
      c Underlined mp are predicted using Lang-Bradley program [19, 20]. 
       d Underlined references were cited in Yalkowsky et al. [8]. 
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